Emily A. Hoyt

Emily A. Hoyt

Auto-generated profile, based on publicly available information

Emily A. Hoyt

Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2019 in Nature Reviews Chemistry
Verified
Journal Article
Closed access
PDF file
EHEmily A. Hoyt
Emily A. Hoyt
PCPedro M. S. D. Cal
Pedro M. S. D. Cal
BOBruno Oliveira
Bruno Oliveira
GBGonçalo J. L. Bernardes
Gonçalo J. L. Bernardes

15 May 2020 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
KMKirsten McAulay
Kirsten McAulay
EHEmily A. Hoyt
Emily A. Hoyt
MTMorgan Thomas
Morgan Thomas
MSMarianne Schimpl
Marianne Schimpl
MBMichael Steven Bodnarchuk
Michael Steven Bodnarchuk
JKJason Grant Kettle
Jason Grant Kettle

27 June 2022 in Nature Chemistry
Verified
Journal Article
Open access
PDF file
LDLavinia Dunsmore
Lavinia Dunsmore
CNClaudio D. Navo
Claudio D. Navo
JBJulie Becher
Julie Becher
EMEnrique Gil de Montes
Enrique Gil de Montes
AGAna Guerreiro
Ana Guerreiro
GBGonçalo J. L. Bernardes
Gonçalo J. L. Bernardes
Natural products that contain ortho-quinones show great potential as anticancer agents but have been largely discarded from clinical development because their redox-cycling behaviour results in general systemic toxicity. Here we report conjugation of ortho-quinones to a carrier, which simultaneously masks their underlying redox activity. C-benzylation at a quinone carbonyl forms a redox-inactive benzyl ketol. Upon a specific enzymatic trigger, an acid-promoted, self-immolative C–C bond-cleaving 1,6-elimination mechanism releases the redox-active hydroquinone inside cells. By using a 5-lipoxygenase modulator, β-lapachone, we created cathepsin-B-cleavable quinone prodrugs. We applied the strategy for intracellular release of β-lapachone upon antibody-mediated delivery. Conjugation of protected β-lapachone to Gem-IgG1 antibodies, which contain the variable region of gemtuzumab, results in homogeneous, systemically non-toxic and conditionally stable CD33+-specific antibody–drug conjugates with in vivo efficacy against a xenograft murine model of acute myeloid leukaemia. This protection strategy could allow the use of previously overlooked natural products as anticancer agents, thus extending the range of drugs available for next-generation targeted therapeutics.

16 March 2022 in Journal of the American Chemical Society
Verified
Journal Article
Open access
XFXhenti Ferhati
Xhenti Ferhati
EJEster Jiménez-Moreno
Ester Jiménez-Moreno
EHEmily A. Hoyt
Emily A. Hoyt
GSGiulia Salluce
Giulia Salluce
MCMar Cabeza-Cabrerizo
Mar Cabeza-Cabrerizo
FCFrancisco Corzana
Francisco Corzana
Antibody-drug conjugates (ADCs) are a class of targeted therapeutics used to selectively kill cancer cells. It is important that they remain intact in the bloodstream and release their payload in the target cancer cell for maximum efficacy and minimum toxicity. The development of effective ADCs requires the study of factors that can alter the stability of these therapeutics at the atomic level. Here, we present a general strategy that combines synthesis, bioconjugation, linker technology, site-directed mutagenesis, and modeling to investigate the influence of the site and microenvironment of the trastuzumab antibody on the stability of the conjugation and linkers. Trastuzumab is widely used to produce targeted ADCs because it can target with high specificity a receptor that is overexpressed in certain breast cancer cells (HER2). We show that the chemical environment of the conjugation site of trastuzumab plays a key role in the stability of linkers featuring acid-sensitive groups such as acetals. More specifically, Lys-207, located near the reactive Cys-205 of a thiomab variant of the antibody, may act as an acid catalyst and promote the hydrolysis of acetals. Mutation of Lys-207 into an alanine or using a longer linker that separates this residue from the acetal group stabilizes the conjugates. Analogously, Lys-207 promotes the beneficial hydrolysis of the succinimide ring when maleimide reagents are used for conjugation, thus stabilizing the subsequent ADCs by impairing the undesired retro-Michael reactions. This work provides new insights for the design of novel ADCs with improved stability properties.

25 January 2020 in Angewandte Chemie
Verified
Journal Article
Closed access
PDF file
EMEnrique Gil de Montes
Enrique Gil de Montes
AIAlena Istrate
Alena Istrate
CNClaudio D. Navo
Claudio D. Navo
EJEster Jiménez‐Moreno
Ester Jiménez‐Moreno
EHEmily A. Hoyt
Emily A. Hoyt
GBGonçalo J. L. Bernardes
Gonçalo J. L. Bernardes